Comparative Pharmacology
Head-to-head clinical analysis: EXNA versus ZIAC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EXNA versus ZIAC.
EXNA vs ZIAC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective serotonin reuptake inhibitor (SSRI): inhibits serotonin (5-HT) reuptake at the presynaptic neuron, increasing serotonin availability in the synaptic cleft.
ZIAC is a combination of bisoprolol, a cardioselective beta1-adrenergic receptor blocker, and hydrochlorothiazide, a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, reducing blood volume.
EXNA is not a recognized drug; no standard dosing available.
ZIAC (bisoprolol fumarate/hydrochlorothiazide) 2.5 mg/6.25 mg to 10 mg/6.25 mg orally once daily, titrated at 2-week intervals based on blood pressure response. Maximum dose: 20 mg/12.5 mg per day.
None Documented
None Documented
Terminal elimination half-life 12-18 hours (mean 14 h) in adults; prolonged in renal impairment (up to 30-40 h in CrCl <30 mL/min).
Bisoprolol: 9–12 h (terminal); HCTZ: 6–15 h (terminal); prolonged in renal impairment; steady state by 5 days
Primarily renal (70% unchanged drug; 15% as metabolites); biliary/fecal (10%); <5% in breast milk.
Renal: bisoprolol (50% unchanged), HCTZ (≥95% unchanged); biliary/fecal: bisoprolol (≤2%)
Category C
Category C
Diuretic
Beta Blocker + Diuretic